UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
RESPONSE ONCOLOGY, INC.
-------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.01 par value per share
-------------------------------------------------------------------------------
(Title of Class of Securities)
761232 30 5
-------------------------------------------------------------------------------
(CUSIP Number)
December 31, 2001
-------------------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/X/ Rule 13d-1(c)
/ / Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
-------------------------------------------------------------------------------
Page 1 of 5 pages
CUSIP NO. 761232 30 5
-------------------------------------------------------------------------------
(1) Names of Reporting Persons
I.R.S. Identification Nos. of Above Persons (entities only)
William D. Grant
-------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member of a Group (a)/ /
(b) / /
Inapplicable
-------------------------------------------------------------------------------
(3) SEC Use Only
-------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
United States
-------------------------------------------------------------------------------
(5) Sole Voting Power
761,333
Number of Shares
Beneficially
---------------------------------------------------------------
Owned by (6) Shared Voting Power
Each 325,194
Reporting
Person
---------------------------------------------------------------
With: (7) Sole Dispositive Power
761,333
---------------------------------------------------------------
(8) Shared Dispositive Power
325,194
-------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned By Each Reporting Person
1,086,527
-------------------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares
/ /
-------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
8.8%
-------------------------------------------------------------------------------
(12) Type of Reporting Person
IN
-------------------------------------------------------------------------------
Page 2 of 5 pages
ITEM 1.
(a) Name of Issuer:
Response Oncology, Inc.
(b) Address of Issuer's Principal Executive Offices:
1775 Moriah Woods Boulevard
Memphis, Tennessee 38117
ITEM 2.
(a) Name of Person Filing:
William D. Grant
(b) Address of Principal Business Office or, if none, Residence:
One Ward Parkway
Suite 130
Kansas City, MO 64112
(c) Citizenship:
United States
(d) Title of Class of Securities:
Common Stock, $0.01 par value per share
(e) CUSIP Number:
761232 30 5
ITEM 3. If this statement is filed pursuant to Sections 240.13d-1(b), or
240.13d-2(b) or (c), check whether the person filing is a:
Not applicable.
Page 3 of 5 pages
ITEM 4. Ownership.
(a) Amount Beneficially Owned: 1,086,527 shares.
The amount of shares reported as beneficially owned includes:
(i) 168,637 shares held by three family trusts, for which the
reporting person acts as co-trustee with UMB Bank, N.A., Kansas City,
Missouri, and in that capacity shares voting and investment powers;
(ii) 86,935 shares held by two family trusts, as to which the
reporting person has the right to direct the voting and disposition
of such shares, and therefore shares voting and investment powers
with the trustee, UMB Bank, N.A.; (iii) 25,629 shares held by a trust
for the benefit of a niece, for which the reporting person acts as
co-trustee with UMB Bank, N.A., and in that capacity shares voting
and investment powers, as to which shares the reporting person
disclaims beneficial ownership; and (iv) 43,993 shares owned by the
reporting person's wife, as to which shares the reporting person
disclaims beneficial ownership.
(b) Percent of Class: 8.8%
(c) Number of shares as to which the person has:
(i) sole power to vote or to direct the vote: 761,333
(ii) shared power to vote or to direct the vote: 325,194
(iii) sole power to dispose or to direct the disposition of:
761,333
(iv) shared power to dispose or to direct the disposition of:
325,194
ITEM 5. Ownership of Five Percent or Less of a Class.
Not applicable.
ITEM 6. Ownership of More Than Five Percent on Behalf of Another Person.
Each trust described in Item 4(a) hereof has the right to receive and
the power to direct the receipt of dividends from, or the proceeds
from the sale of, 281,201 shares of Common Stock of the Issuer held
by such trust.
ITEM 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding Company.
Not applicable.
ITEM 8. Identification and Classification of Members of the Group.
Not applicable.
Page 4 of 5 pages
ITEM 9. Notice of Dissolution of Group.
Not applicable.
ITEM 10. Certification.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not
acquired and are not held in connection with or as a participant in
any transaction having that purpose or effect.
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
/s/ W. D. Grant
------------------------------------------
W.D. Grant
Dated: February 14, 2002
5 of 5 pages